Parnax Lab (PARNAXLAB)₹108.45+1.36%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Parnax Lab reported sales of ₹56.75 Cr, up 6.4% from Jun 2025, and net profit of ₹0.44 Cr, down 86.6% year on year. For the year to Mar 2026, sales were ₹249 Cr and net profit ₹12.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.58 | 50.93 | 46.32 | 50.07 | 48.37 | 40.19 | 48.98 | 53.36 | 62.58 | 62.90 | 69.64 | 56.75 |
| Expenses | 37.35 | 45.09 | 40.63 | 41.54 | 41.20 | 36.02 | 42.48 | 46.03 | 54.59 | 56.20 | 64.84 | 52.59 |
| Operating Profit | 5.27 | 5.94 | 5.77 | 8.59 | 7.22 | 4.25 | 6.60 | 7.41 | 8.05 | 6.82 | 4.86 | 4.30 |
| OPM % | 12.4% | 11.6% | 12.4% | 17.1% | 14.9% | 10.6% | 13.5% | 13.9% | 12.9% | 10.9% | 7.0% | 7.5% |
| Other Income | 0.23 | 0.11 | 0.26 | 0.12 | 0.96 | 0.20 | 0.44 | 0.19 | 0.64 | −0.18 | 1.77 | 0.16 |
| Interest | 1.42 | 1.34 | 1.40 | 1.49 | 1.37 | 1.22 | 1.27 | 1.21 | 1.39 | 1.46 | 1.60 | 1.63 |
| Depreciation | 1.73 | 1.77 | 1.83 | 1.82 | 1.93 | 1.78 | 1.82 | 1.93 | 2.09 | 1.95 | 2.03 | 2.21 |
| Profit before tax | 2.35 | 2.95 | 2.80 | 5.41 | 4.88 | 1.45 | 3.96 | 4.47 | 5.22 | 3.26 | 3.00 | 0.61 |
| Tax % | 20.1% | 25.8% | 19.3% | 26.3% | 29.8% | 16.7% | 26.1% | 26.4% | 30.3% | 16.6% | 27.1% | 28.3% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 |
| Net Profit | 1.88 | 2.19 | 2.25 | 4.00 | 3.43 | 1.22 | 2.94 | 3.29 | 3.63 | 2.72 | 2.20 | 0.44 |
| EPS (Rs) | 1.62 | 1.89 | 1.94 | 3.46 | 2.96 | 1.04 | 2.53 | 2.84 | 3.15 | 2.35 | 1.89 | 0.36 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.95 | 94.91 | 106 | 109 | 94.90 | 89.94 | 163 | 168 | 189 | 188 | 249 | 252 |
| Expenses | 61.06 | 82.06 | 95.19 | 99.11 | 89.10 | 80.11 | 140 | 145 | 165 | 161 | 221 | 228 |
| Operating Profit | 9.97 | 12.95 | 9.96 | 9.96 | 5.98 | 9.95 | 22.91 | 22.92 | 23.91 | 26.90 | 26.89 | 24.03 |
| OPM % | 13.9% | 13.9% | 10.0% | 9.0% | 7.0% | 10.9% | 13.9% | 14.0% | 11.9% | 14.0% | 10.9% | 9.5% |
| Other Income | 1.01 | 0.00 | 1.01 | 2.01 | 1.01 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 2.01 | 2.39 |
| Interest | 3.98 | 4.98 | 3.99 | 3.99 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 | 5.98 | 6.08 |
| Depreciation | 2.99 | 3.98 | 3.98 | 3.98 | 3.98 | 4.98 | 5.97 | 6.97 | 6.98 | 6.98 | 7.97 | 8.28 |
| Profit before tax | 3.01 | 5.01 | 3.01 | 5.01 | −2.01 | 0.00 | 12.02 | 12.01 | 12.01 | 16.03 | 16.03 | 12.09 |
| Tax % | 28.0% | 22.0% | 65.0% | 28.0% | 48.0% | 350.0% | 33.0% | 30.0% | 20.0% | 26.0% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | −0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | −0.20 | −1.03 | −1.01 |
| Net Profit | 3.01 | 4.01 | 1.01 | 3.01 | −3.01 | 0.00 | 8.01 | 9.02 | 10.02 | 12.03 | 12.01 | 8.99 |
| EPS (Rs) | 2.94 | 4.32 | 1.22 | 3.87 | −3.41 | −0.41 | 8.38 | 7.50 | 8.35 | 10.00 | 10.24 | 7.75 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.98 | 7.99 | 7.98 | 7.99 | 7.99 | 7.99 | 7.99 | 9.99 | 10.98 | 10.98 | 10.98 | 10.97 |
| Reserves | 17.05 | 19.05 | 23.06 | 24.06 | 27.08 | 24.07 | 24.06 | 38.06 | 51.10 | 60.11 | 72.11 | 84.23 |
| Borrowings | 40.85 | 41.85 | 38.85 | 36.88 | 41.88 | 50.85 | 58.81 | 68.72 | 54.82 | 80.73 | 69.75 | 82.73 |
| Other Liabilities | 17.01 | 10.05 | 15.06 | 18.02 | 17.03 | 23.06 | 15.03 | 36.10 | 28.08 | 38.03 | 37.05 | 49.99 |
| Total Liabilities | 82.89 | 78.94 | 85.95 | 86.95 | 94.98 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Fixed Assets | 36.05 | 38.06 | 47.04 | 44.09 | 51.09 | 58.08 | 60.03 | 72.07 | 77.13 | 89.08 | 88.05 | 115 |
| CWIP | 1.01 | 2.01 | 0.00 | 0.00 | 0.00 | 3.01 | 5.01 | 3.01 | 2.01 | 21.02 | 29.04 | 11.01 |
| Investments | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 44.84 | 37.88 | 37.91 | 42.86 | 42.89 | 45.88 | 40.85 | 77.79 | 65.84 | 79.75 | 71.80 | 101 |
| Inventories | 7.06 | 6.66 | 7.96 | 7.70 | 8.50 | 11.20 | 10.83 | 20.01 | 21.78 | 30.03 | 25.85 | 36.37 |
| Trade receivables | 23.53 | 19.47 | 18.68 | 18.70 | 19.22 | 23.11 | 16.74 | 38.14 | 27.92 | 32.63 | 30.79 | 37.87 |
| Cash & equivalents | 2.35 | 0.39 | 1.12 | 1.60 | 0.61 | 1.29 | 1.28 | 5.77 | 2.79 | 1.89 | 2.69 | 2.27 |
| Total Assets | 82.89 | 78.94 | 85.95 | 86.95 | 94.98 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 3.01 | 16.04 | 13.03 | 9.02 | 9.01 | 6.01 | 9.02 | 21.03 | 16.04 | 32.04 | 8.01 |
| Cash from investing activity | −3.99 | −5.99 | −9.98 | −4.99 | −10.98 | −12.97 | −6.99 | −15.97 | −9.98 | −31.92 | −15.95 | −15.96 |
| Cash from financing activity | 6.02 | 1.01 | −5.02 | −7.03 | 1.01 | 5.01 | 0.00 | 12.05 | −14.04 | 15.05 | −16.06 | 8.02 |
| Net cash flow | 1.01 | −2.01 | 0.00 | 1.01 | −1.01 | 0.00 | 0.00 | 4.01 | −3.01 | −1.01 | 0.00 | 0.00 |
| Capex | 3.80 | 6.15 | 10.87 | 5.24 | 11.35 | 13.23 | 4.56 | 17.90 | 11.33 | 14.19 | 9.79 | 35.58 |
| Free cash flow | −4.01 | −3.01 | 5.02 | 8.03 | −3.01 | −4.01 | 0.00 | −8.03 | 11.04 | −16.07 | 16.06 | −9.03 |
| CFO / OP % | 15.0% | 46.0% | 134.0% | 134.0% | 99.0% | 153.0% | 71.0% | 38.0% | 103.0% | 79.0% | 130.0% | 42.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 83 | 99 | 71 | 64 | 63 | 87 | 67 | 84 | 60 | 62 | 59 | 55 |
| Inventory days | 39 | 65 | 51 | 46 | 53 | 77 | 81 | 74 | 80 | 95 | 88 | 91 |
| Days payable | 51 | 30 | 48 | 45 | 44 | 74 | 46 | 81 | 53 | 74 | 72 | 80 |
| Cash conversion cycle | 71 | 134 | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 83 | 75 | 65 |
| Working capital days | 16 | 7 | −26 | −8 | 0 | −31 | −66 | −35 | −19 | −23 | −24 | −11 |
| ROCE % | 16.1% | 11.1% | 14.1% | 11.1% | 12.1% | 3.0% | 6.0% | 17.1% | 15.1% | 13.1% | 14.1% | 14.1% |
For the Jun 2026 quarter, Parnax Lab reported sales of ₹56.75 Cr, up 6.4% year on year and net profit of ₹0.44 Cr, down 86.6% year on year. The operating margin was 7.5%.
Parnax Lab's sales for the year to Mar 2026 were ₹249 Cr; over the last twelve months they were ₹252 Cr.
Net profit for the year to Mar 2026 was ₹12.01 Cr, and ₹8.99 Cr over the last twelve months. Earnings per share over the same trailing period were ₹7.75.
Parnax Lab reported borrowings of ₹82.73 Cr at Mar 2026, against cash and equivalents of ₹2.27 Cr.
Cash from operations was ₹8.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹9.03 Cr.